These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 37111540)

  • 1. Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer's Disease.
    Moreira DA; Santos SD; Leiro V; Pêgo AP
    Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanotherapeutics for Alzheimer's Disease with Preclinical Evaluation and Clinical Trials: Challenges, Promises and Limitations.
    Bukhari SNA
    Curr Drug Deliv; 2022; 19(1):17-31. PubMed ID: 34514990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendrimer-based nanocarriers: a versatile platform for drug delivery.
    Hsu HJ; Bugno J; Lee SR; Hong S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2017 Jan; 9(1):. PubMed ID: 27126551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's Disease - Future Therapy Based on Dendrimers.
    Aliev G; Ashraf GM; Tarasov VV; Chubarev VN; Leszek J; Gasiorowski K; Makhmutovа A; Baeesa SS; Avila-Rodriguez M; Ustyugov AA; Bachurin SO
    Curr Neuropharmacol; 2019; 17(3):288-294. PubMed ID: 30227819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review on ferulic acid and analogs based scaffolds for the management of Alzheimer's disease.
    Singh YP; Rai H; Singh G; Singh GK; Mishra S; Kumar S; Srikrishna S; Modi G
    Eur J Med Chem; 2021 Apr; 215():113278. PubMed ID: 33662757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic Insight into the Design of Chemical Tools to Control Multiple Pathogenic Features in Alzheimer's Disease.
    Han J; Du Z; Lim MH
    Acc Chem Res; 2021 Oct; 54(20):3930-3940. PubMed ID: 34606227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More than Just Size: Challenges and Opportunities of Hybrid Dendritic Nanocarriers.
    Rimondino GN; Oksdath-Mansilla G; Brunetti V; Strumia MC
    Curr Pharm Des; 2017; 23(21):3142-3153. PubMed ID: 28403793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendrimers in Alzheimer's Disease: Recent Approaches in Multi-Targeting Strategies.
    Arbez-Gindre C; Steele BR; Micha-Screttas M
    Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.
    Morató X; Pytel V; Jofresa S; Ruiz A; Boada M
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendrimers: Patents for Alzheimer's Disease.
    Maheshwari S; Singh A
    Recent Pat Nanotechnol; 2023 Oct; ():. PubMed ID: 37904560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical diagonal translation of nanoparticles: Case studies in dendrimer nanomedicine.
    Mignani S; Shi X; Guidolin K; Zheng G; Karpus A; Majoral JP
    J Control Release; 2021 Sep; 337():356-370. PubMed ID: 34311026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorus dendrimers affect Alzheimer's (Aβ1-28) peptide and MAP-Tau protein aggregation.
    Wasiak T; Ionov M; Nieznanski K; Nieznanska H; Klementieva O; Granell M; Cladera J; Majoral JP; Caminade AM; Klajnert B
    Mol Pharm; 2012 Mar; 9(3):458-69. PubMed ID: 22206488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical applications of dendrimers: promising nanocarriers for drug delivery.
    Cheng Y; Wang J; Rao T; He X; Xu T
    Front Biosci; 2008 Jan; 13():1447-71. PubMed ID: 17981642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendrimers as nanocarriers for nucleoside analogues.
    Gorzkiewicz M; Klajnert-Maculewicz B
    Eur J Pharm Biopharm; 2017 May; 114():43-56. PubMed ID: 28089915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dense shell glycodendrimers as potential nontoxic anti-amyloidogenic agents in Alzheimer's disease. Amyloid-dendrimer aggregates morphology and cell toxicity.
    Klementieva O; Benseny-Cases N; Gella A; Appelhans D; Voit B; Cladera J
    Biomacromolecules; 2011 Nov; 12(11):3903-9. PubMed ID: 21936579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer's Disease.
    Mashal Y; Abdelhady H; Iyer AK
    Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendrimer toxicity: Let's meet the challenge.
    Jain K; Kesharwani P; Gupta U; Jain NK
    Int J Pharm; 2010 Jul; 394(1-2):122-42. PubMed ID: 20433913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.